First Light Asset Management LLC Invests $56.98 Million in Twist Bioscience Co. (NASDAQ:TWST)

First Light Asset Management LLC acquired a new stake in Twist Bioscience Co. (NASDAQ:TWST - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 1,226,255 shares of the company's stock, valued at approximately $56,984,000. Twist Bioscience comprises 5.4% of First Light Asset Management LLC's investment portfolio, making the stock its 5th largest holding. First Light Asset Management LLC owned 2.06% of Twist Bioscience at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of TWST. Wilmington Savings Fund Society FSB bought a new position in Twist Bioscience in the 3rd quarter worth approximately $34,000. Van ECK Associates Corp increased its position in Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock worth $34,000 after acquiring an additional 267 shares during the period. US Bancorp DE raised its stake in Twist Bioscience by 72.0% during the 4th quarter. US Bancorp DE now owns 1,436 shares of the company's stock valued at $67,000 after purchasing an additional 601 shares during the last quarter. Beaird Harris Wealth Management LLC acquired a new stake in Twist Bioscience in the 3rd quarter worth $95,000. Finally, KBC Group NV increased its holdings in shares of Twist Bioscience by 71.4% during the 4th quarter. KBC Group NV now owns 2,942 shares of the company's stock worth $137,000 after purchasing an additional 1,226 shares during the period.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Guggenheim set a $50.00 price objective on shares of Twist Bioscience in a research note on Friday, March 28th. Robert W. Baird increased their target price on Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a report on Tuesday, February 4th. Scotiabank reaffirmed an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Barclays cut their price objective on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $52.80.

Twist Bioscience Trading Down 1.6 %

Shares of NASDAQ TWST traded down $0.61 during midday trading on Thursday, hitting $37.71. The stock had a trading volume of 1,178,289 shares, compared to its average volume of 979,593. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. Twist Bioscience Co. has a fifty-two week low of $30.73 and a fifty-two week high of $60.90. The firm has a market cap of $2.25 billion, a P/E ratio of -11.16 and a beta of 2.34. The company's 50-day simple moving average is $39.27 and its 200 day simple moving average is $44.12.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company had revenue of $88.70 million during the quarter, compared to analysts' expectations of $86.96 million. During the same quarter in the previous year, the company posted ($0.75) EPS. The business's revenue for the quarter was up 24.1% compared to the same quarter last year. Research analysts anticipate that Twist Bioscience Co. will post -2.12 EPS for the current year.

Insider Transactions at Twist Bioscience

In other news, insider Dennis Cho sold 806 shares of the business's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total value of $39,776.10. Following the completion of the transaction, the insider now owns 112,221 shares of the company's stock, valued at $5,538,106.35. The trade was a 0.71 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert Chess sold 2,940 shares of Twist Bioscience stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $53.13, for a total value of $156,202.20. Following the transaction, the director now owns 18,173 shares in the company, valued at approximately $965,531.49. This represents a 13.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 22,432 shares of company stock worth $1,038,170. 3.01% of the stock is currently owned by company insiders.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.